APA

Papp K., Thaçi D., Reich K., Riedl E., Langley R. G., Krueger J. G., Gottlieb A. B., Nakagawa H., Bowman E. P., Mehta A., Li Q., Zhou Y. & Shames R. (20160913). Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. : The British journal of dermatology.

Chicago

Papp K, Thaçi D, Reich K, Riedl E, Langley R G, Krueger J G, Gottlieb A B, Nakagawa H, Bowman E P, Mehta A, Li Q, Zhou Y and Shames R. 20160913. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. : The British journal of dermatology.

Harvard

Papp K., Thaçi D., Reich K., Riedl E., Langley R. G., Krueger J. G., Gottlieb A. B., Nakagawa H., Bowman E. P., Mehta A., Li Q., Zhou Y. and Shames R. (20160913). Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. : The British journal of dermatology.

MLA

Papp K, Thaçi D, Reich K, Riedl E, Langley R G, Krueger J G, Gottlieb A B, Nakagawa H, Bowman E P, Mehta A, Li Q, Zhou Y and Shames R. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. : The British journal of dermatology. 20160913.